Generic GLP-1s Are Coming, but Americans Don’t Want to Wait

Key Takeaways

• US GLP‑1 usage rose to 12.4% in two years
• Global GLP‑1 market projected to reach $135 billion by 2034
• Canada expects generic semaglutide by 2026 after patent lapse
• FDA warns against unapproved compounded GLP‑1s
• GLP‑1s could boost US GDP by 0.4% via productivity

Summary

GLP‑1 drugs such as semaglutide have surged from diabetes treatment to a mass‑market weight‑loss solution, with roughly 12.4% of Americans now using them. Global sales are projected to climb from $50‑60 billion today to over $135 billion within a decade, driven largely by North America. A patent lapse in Canada will allow generic semaglutide to appear as early as 2026, while the United States still faces no FDA‑approved generics and a growing grey market of compounded products. The FDA is intensifying enforcement against unapproved compounding pharmacies.

Pulse Analysis

The rapid adoption of GLP‑1 agonists has turned them into the pharmaceutical industry’s newest blockbuster. Originally approved for type‑2 diabetes, drugs like semaglutide quickly proved effective for weight loss, prompting a surge in prescriptions that now touches one in eight Americans. This unprecedented uptake is fueling a market expansion that analysts expect to more than double in the next ten years, positioning GLP‑1s as a dominant revenue driver for manufacturers and a catalyst for new therapeutic research.

In Canada, a seemingly accidental lapse of Novo Nordisk’s maintenance fee has opened the door for generic semaglutide as early as 2026. Multiple domestic manufacturers are preparing to launch lower‑cost versions, promising to slash retail prices that currently hover around $1,000 per month in the United States. The Canadian scenario offers a preview of how patent strategy and regulatory timing can dramatically affect drug affordability, and it underscores the pressure on U.S. policymakers to address the lingering absence of approved generics.

Meanwhile, the United States is grappling with a burgeoning grey market of compounded GLP‑1 products. These unapproved formulations bypass FDA review, raising safety concerns and prompting a recent enforcement wave targeting telehealth providers. Beyond health risks, the widespread use of GLP‑1s is already influencing macro‑economic indicators, with Goldman Sachs estimating a 0.4% boost to U.S. GDP through productivity gains and reduced healthcare costs. As price pressures mount, the industry’s next challenge will be balancing rapid innovation with equitable access and robust regulatory oversight.